Answers are grounded in this paper and cite their sources.
Obeticholic acid administered with ursodiol or as monotherapy for 12 months in patients with primary biliary cholangitis resulted in decreases from baseline in alkaline phosphatase and total bilirubin levels that differed significantly from the changes observed with placebo. There were more serious adverse events with obeticholic acid. (Funded by Intercept Pharmaceuticals; POISE ClinicalTrials.gov number, NCT01473524; Current Controlled Trials number, ISRCTN89514817.).
No takes yet. Share an insight, caveat, or question.
Nevens et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: